323 related articles for article (PubMed ID: 27879367)
1. Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.
Chen K; Xiao H; Zeng J; Yu G; Zhou H; Huang C; Yao W; Xiao W; Hu J; Guan W; Wu L; Huang J; Huang Q; Xu H; Ye Z
Clin Cancer Res; 2017 Jul; 23(13):3428-3441. PubMed ID: 27879367
[No Abstract] [Full Text] [Related]
2. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
3. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
4. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.
Xu T; Li X; Zhao W; Wang X; Jin L; Feng Z; Li H; Zhang M; Tian Y; Hu G; Yue Y; Dai X; Shan C; Zhang W; Zhang C; Zhang Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):126. PubMed ID: 38671459
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA UFC1 acts as an oncogene via stimulating EZH2-induced inhibition of APC expression in renal cell carcinoma.
Wang J; Liu G
Cell Mol Biol (Noisy-le-grand); 2023 Apr; 69(4):152-156. PubMed ID: 37329532
[TBL] [Abstract][Full Text] [Related]
6. MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.
Liu L; Luo C; Luo Y; Chen L; Liu Y; Wang Y; Han J; Zhang Y; Wei N; Xie Z; Wu W; Wu G; Feng Y
Oncogene; 2018 Jan; 37(1):86-94. PubMed ID: 28869607
[TBL] [Abstract][Full Text] [Related]
7. RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability.
Wu Y; Xu Z; Chen X; Fu G; Tian J; Jin B
Cancer Med; 2023 Oct; 12(19):19889-19903. PubMed ID: 37747077
[TBL] [Abstract][Full Text] [Related]
8. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt/β-catenin signaling pathway in clear cell renal cell carcinoma.
Huang JL; Liao Y; Qiu MX; Li J; An Y
Tumour Biol; 2017 Jul; 39(7):1010428317711314. PubMed ID: 28718366
[TBL] [Abstract][Full Text] [Related]
10. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
11. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
12. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Tao T; Yang X; Zheng J; Feng D; Qin Q; Shi X; Wang Q; Zhao C; Peng Z; Liu H; Jiang WG; He J
Oncogene; 2017 Nov; 36(44):6119-6131. PubMed ID: 28692056
[TBL] [Abstract][Full Text] [Related]
13. MiR-337-3p suppresses the proliferation and metastasis of clear cell renal cell carcinoma cells via modulating Capn4.
Zhuang Q; Shen J; Chen Z; Zhang M; Fan M; Xue D; Lu H; Xu R; He X; Hou J
Cancer Biomark; 2018; 23(4):515-525. PubMed ID: 30452399
[TBL] [Abstract][Full Text] [Related]
14. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription.
Zhang KJ; Tan XL; Guo L
Mol Oncol; 2020 Feb; 14(2):309-328. PubMed ID: 31860165
[TBL] [Abstract][Full Text] [Related]
17. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
18. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
19. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
Xu ZQ; Zhang L; Gao BS; Wan YG; Zhang XH; Chen B; Wang YT; Sun N; Fu YW
Clin Transl Oncol; 2015 Jan; 17(1):41-9. PubMed ID: 24986100
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia alters splicing of the cancer associated Fas gene.
Peciuliene I; Vilys L; Jakubauskiene E; Zaliauskiene L; Kanopka A
Exp Cell Res; 2019 Jul; 380(1):29-35. PubMed ID: 31002816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]